Protective Effects of a Modified Vaccinia Ankara-based Vaccine Candidate Against Crimean-Congo Haemorrhagic Fever Virus Require Both Cellular and Humoral Responses

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jun 9

PMID 27272940

Citations 46

Authors

Stuart D Dowall

Victoria A Graham

Emma Rayner

Laura Hunter

Robert Watson

Irene Taylor

Antony Rule

Miles W Carroll

Roger Hewson

Affiliations

Soon will be listed here.

Abstract

Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. There is no approved vaccine currently available against CCHF. The most promising candidate, which has previously been shown to confer protection in the small animal model, is a modified Vaccinia Ankara virus vector expressing the CCHF viral glycoprotein (MVA-GP). It has been shown that MVA-GP induces both humoral and cellular immunogenicity. In the present study, sera and T-lymphocytes were passively and adoptively transferred into recipient mice prior to challenge with CCHF virus. Results demonstrated that mediators from both arms of the immune system were required to demonstrate protective effects against lethal challenge.

Citing Articles

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine.

Kennedy E, Hewson R, Dowall S Methods Mol Biol. 2024; 2893:257-272.

PMID: 39671043 DOI: 10.1007/978-1-0716-4338-9_19.

The Role of Nucleocapsid Protein (NP) in the Immunology of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).

Pirincal A, Doymaz M Viruses. 2024; 16(10).

PMID: 39459881 PMC: 11512346. DOI: 10.3390/v16101547.

Interventions for the control of Crimean-Congo hemorrhagic fever and tick vectors.

de la Fuente J, Ghosh S, Lempereur L, Garrison A, Sprong H, Lopez-Camacho C NPJ Vaccines. 2024; 9(1):181.

PMID: 39353956 PMC: 11445411. DOI: 10.1038/s41541-024-00970-5.

Cellular immunity to nucleoproteins (NP) of Crimean-Congo hemorrhagic fever virus (CCHFV) and Hazara Virus (HAZV).

Kalkan-Yazici M, Karaaslan E, Guler-Cetin N, Doymaz M Med Microbiol Immunol. 2024; 213(1):20.

PMID: 39320473 DOI: 10.1007/s00430-024-00802-2.

Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever.

Sarmadi S, Ghalyanchilangeroudi A, Najafi H Virusdisease. 2024; 35(2):377-383.

PMID: 39071873 PMC: 11269551. DOI: 10.1007/s13337-024-00868-9.

References

Arda B, Aciduman A, Johnston J . A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations. J Med Ethics. 2011; 38(2):117-20. DOI: 10.1136/medethics-2011-100107. View

Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan K . Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother. 2011; 66(6):1215-22. DOI: 10.1093/jac/dkr136. View

Schmaljohn C, Parker M, Ennis W, Dalrymple J, Collett M, Suzich J . Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology. 1989; 170(1):184-92. DOI: 10.1016/0042-6822(89)90365-6. View

Buttigieg K, Dowall S, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R . A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PLoS One. 2014; 9(3):e91516. PMC: 3951450. DOI: 10.1371/journal.pone.0091516. View

Du X, Jin R, Ning N, Li L, Wang Q, Liang W . In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep. 2012; 28(5):1743-9. DOI: 10.3892/or.2012.2013. View

Shrestha B, Samuel M, Diamond M . CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol. 2005; 80(1):119-29. PMC: 1317548. DOI: 10.1128/JVI.80.1.119-129.2006. View

Canakoglu N, Berber E, Tonbak S, Ertek M, Sozdutmaz I, Aktas M . Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Negl Trop Dis. 2015; 9(3):e0003579. PMC: 4356576. DOI: 10.1371/journal.pntd.0003579. View

Ergonul O . Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006; 6(4):203-14. PMC: 7185836. DOI: 10.1016/S1473-3099(06)70435-2. View

Akira S . Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 1999; 17(3):138-46. DOI: 10.1002/stem.170138. View

10.

Custer D, Thompson E, Schmaljohn C, Ksiazek T, Hooper J . Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003; 77(18):9894-905. PMC: 224585. DOI: 10.1128/jvi.77.18.9894-9905.2003. View

11.

Holzer G, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S . Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine. 2011; 29(24):4132-41. DOI: 10.1016/j.vaccine.2011.03.089. View

12.

Keshtkar-Jahromi M, Kuhn J, Christova I, Bradfute S, Jahrling P, Bavari S . Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res. 2011; 90(2):85-92. DOI: 10.1016/j.antiviral.2011.02.010. View

13.

Wilson J, HART M . Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol. 2001; 75(6):2660-4. PMC: 115890. DOI: 10.1128/JVI.75.6.2660-2664.2001. View

14.

Maltezou H, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F . Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro Surveill. 2010; 15(10):19504. View

15.

Ghiasi S, Salmanian A, Chinikar S, Zakeri S . Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol. 2011; 18(12):2031-7. PMC: 3232705. DOI: 10.1128/CVI.05352-11. View

16.

Shepherd A, Swanepoel R, Leman P . Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989; 11 Suppl 4:S801-6. DOI: 10.1093/clinids/11.supplement_4.s801. View

17.

Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A . Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine. 2012; 30(44):6225-9. DOI: 10.1016/j.vaccine.2012.08.003. View

18.

Petersen C, Petersen M, Agger R, Hokland M . Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection. J Immunother. 2006; 29(3):241-9. DOI: 10.1097/01.cji.0000203078.97493.c3. View

19.

Bereczky S, Lindegren G, Karlberg H, Akerstrom S, Klingstrom J, Mirazimi A . Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol. 2010; 91(Pt 6):1473-7. DOI: 10.1099/vir.0.019034-0. View

20.

Muller U, Steinhoff U, Reis L, Hemmi S, Pavlovic J, Zinkernagel R . Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167):1918-21. DOI: 10.1126/science.8009221. View